Investigational drug · Phase 2
INI-2004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Allergic Rhinitis Due to Allergens, Rhinitis Allergic, Allergic Rhinitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "INI-2004"
First trial start
2026
Jan 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INI-2004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Rhinitis Due to Allergens
- Rhinitis Allergic
- Allergic Rhinitis
Approved drugs for the same conditions: Allergies (allergic rhinitis)
Largest trials
Live from ClinicalTrials.gov: studies naming "INI-2004" as an intervention, largest first.
Inimmune CorporationIndustry
NCT07556393 · 78 participants · Start Jan 19, 2026 · Primary completion Apr 23, 2026
Drug: INI-2004 · For: Allergic Rhinitis Due to Allergens; Rhinitis Allergic; Allergic Rhinitis
Sites: Kingston, Canada
Inimmune CorporationIndustry
NCT06038279 · 68 participants · Start Jul 4, 2023 · Primary completion Sep 5, 2024
Drug: INI-2004; Placebo · For: Allergic Rhinitis Due to Weed Pollen; Allergic Rhinitis
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants.
Richardson RA, Moon C, Sands CM, et al. · Vaccine 2026
- Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization.
Jackson KJ, Buhl C, Miller SM, et al. · Front Immunol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.